Transcenta Holding Limited has announced a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc., a global biopharmaceutical development and manufacturing company. Under the agreement, EirGenix will receive a non-exclusive license to use Transcenta’s Highly Intensified Continuous Bioprocessing (HiCB) platform, which includes advanced continuous perfusion and hybrid purification technologies, comprehensive process documentation, know-how, and regulatory support. Transcenta will receive substantial upfront and milestone payments, as well as future royalties from the commercial use of the licensed technologies. The partnership aims to enhance process efficiency, reduce manufacturing costs, and expand global access to affordable biologics.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251229-11968025), on December 28, 2025, and is solely responsible for the information contained therein.
